London – A new modelling analysis by AstraZeneca, IMPACT CKD, forecasts up to 16.5% of the population across eight countries will suffer from chronic kidney disease (CKD) by 2032, including a rise of up to 59.3% in advanced-stage.1 Presented at the 2024 ISN World Congress of Nephrology (WCN’24) in Buenos Aires, the study highlights an urgent and growing global health crisis …
London – Positive results from the T2NOW Phase III trial demonstrated significant reduction in A1C, a marker of average blood sugar, for patients treated with Forxiga (dapagliflozin) compared with patients receiving placebo.1,2 Adjusted mean change in A1C was −0.62% for Forxiga versus +0.41% for placebo, a difference of −1.03% (95% CI: -1.57-0.49; p<0.001). Statistical significance was achieved in the primary endpoint and in all …
New data from Fasenra and Tezspire trials demonstrate AstraZeneca biologics progress towards achieving remission in severe asthma New EXACOS-CV data uncover increased cardiopulmonary risk following COPD exacerbations London – AstraZeneca will present new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the European Respiratory Society (ERS) International Congress 2023, in Milan, Italy from …
AstraZeneca will present 19 abstracts, including 10 oral presentations and five late-breaking presentations, at the European Society of Cardiology (ESC) Congress from 25-28 August 2023, which includes data highlighting the opportunities for improved management in heart failure (HF), and AstraZeneca’s leadership across the interconnectedness of chronic diseases. Among these abstracts will be sub-analyses from the DELIVER trial – a trial …
